Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells

Fig. 3

Sorafenib causes MPM TIC cell cycle arrest in the G0/G1 phase. a Representative cell cycle profiles of MM1, MM3, and MM4 cells treated with IC50 sorafenib or vehicle for 48 h before harvest, determined by staining with PI for DNA content analysis and counting on a FACScalibur. b Acquired FACS data were analyzed by ModFit LT software and the cell cycle phase distribution determined. Data correspond to mean ± SD of three independent experiments. *p <0.05, **p <0.01, ***p <0.001 vs respective controls. CTR control, SOR sorafenib

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512